-

Jury Finds in Favor of Monsanto in Philadelphia Trial

Young decision marks 14th favorable outcome in last 20 trials for Company

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, the jury reached a verdict in the Young Roundup™ product liability trial before Judge Angelo Foglietta in the Philadelphia Court of Common Pleas.

In response to the decision, Monsanto issued the following statement:

“The jury’s verdict in favor of the Company marks the 14th favorable outcome in the last 20 trials and validates the Company’s strategy of taking cases to trial based on strong scientific and regulatory evidence. The verdict makes clear that the plaintiff failed to prove that Roundup™ was the cause of the injuries alleged in this case, consistent with the scientific evidence and the consensus of regulatory bodies and their scientific assessments worldwide. While we have great sympathy for anyone who suffers a loss or injury, the science proves that Roundup™ is not carcinogenic.

“This verdict follows the favorable ruling from the Third Circuit Court of Appeals in Schaffner v. Monsanto, which unanimously held that the state-based failure-to-warn claims central to these cases are expressly preempted by the federal law, since the U.S. EPA has repeatedly concluded the product does not cause cancer and approved the product label without any such warning. The Company is actively taking steps to apply the Schaffner ruling to other Roundup™ cases and looks forward to presenting its arguments, as fully embraced by the Third Circuit, at trial courts, appellate courts, and the U.S. Supreme Court.

“Additionally, outside the courtroom, we will continue supporting legislation at the state and federal level alongside hundreds of agricultural organizations to ensure that any pesticide reviewed and registered by the U.S. EPA – and sold under a label consistent with the EPA’s determinations – is sufficient to satisfy requirements for health and safety warnings. Without legislative certainty, the litigation industry will continue to target crop protection tools that have been deemed safe by experts at the U.S. EPA.

“We continue to stand fully behind the safety of Roundup™ products – critical tools that farmers rely on to produce affordable food and feed the world.”

Contacts

Media
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Media
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared to placebo, both in combination with antiplatelet therapy. Asundexian significantly reduced ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p<.0001), in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase i...

Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign...

Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention

BERLIN--(BUSINESS WIRE)--Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two late-breaking sessions at the upcoming American Stroke Association’s International Stroke Conference (ISC) 2026. The conference will be held February 4-6 in New Orleans, Louisiana, USA. The research to be presented demonstrates the longstanding commitment of Bayer as a leader in cardiovascular and...
Back to Newsroom